Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work GlobeNewswire November 04, 2025 CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it […]

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 7th Annual Wolfe Research Healthcare Conference on Tuesday, Nov. 18 at 10:00 a.m. ET. https://mma.prnewswire.com/media/2460831/Grail_Logo.jpg Live and replay webcasts may be accessed in the investor relations section

Acquisition brings next-generation, cloud-native 911 technology into the Axon ecosystem, uniting connected devices, real-time communications, and digital evidence from call to courtroom. Axon (Nasdaq: AXON), the global public safety technology leader, today announced it has entered into a definitive agreement to acquire Carbyne, an innovative emergency communications and response platform serving hundreds of agencies protecting

— Third quarter 2025 total revenue of approximately $69.5 million, including record net product sales of $64.1 million and contract revenues from collaborations of $5.4 million — Generated $27.9 million of net income in the third quarter of 2025 — Completed enrollment in the dose escalation phase and enrolled the first patient in the dose

NASHVILLE, TN / ACCESS Newswire / November 4, 2025 / First Acceptance Corporation (OTCQX:FACO) today reported its financial results for the quarter ended September 30, 2025. A quarterly report can be found at www.otcmarkets.com/stock/FACO/disclosure. Revenues for the three months ended September 30, 2025 increased 9% to $140.7 million from $129.3 million in the same period

Iridium Communications Inc. (Nasdaq: IRDM) (“Iridium”), a leading provider of global voice, data and PNT satellite services,today announced that Company executives would participate in upcoming investor conferences: https://mma.prnewswire.com/media/1394616/IRIDIUM_Logo.jpg — The Deutsche Bank Global Space Summit on Wednesday, November 19, 2025. — The Bank of America Leveraged Finance Conference on Tuesday, December 2, 2025. — The

Initiated US and EU launch of Sephience™ (sepiapterin) – Strong initial Sephience uptake with global revenue of $19.6M and 521 start forms in the US as of September 30 – Robust Q3 performance with total revenue of $211M – Full-year 2025 revenue guidance narrowed to $750 – $800M – PTC Therapeutics, Inc., (NASDAQ: PTCT) today

New Phase 1 PK Data Support Once-Weekly Dosing; Clinically Meaningful Weight Loss Observed Without Dose Titration DA-1726 Achieves Superior Lipid-Lowering Effects and Comparable Weight Loss to Pemvidutide in Pre-clinical Models MetaVia Inc. (Nasdaq: MTVA),a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will present new Phase 1 and pre-clinical data on

https://mma.prnewswire.com/media/231466/axon_logo.jpg — Software & Services revenue grows 41% to $305 million — Annual recurring revenue grows 41% to $1.3 billion — Net loss was $2 million, with non-GAAP net income of $98 million and Adjusted EBITDA of $177 million — Raises full year revenue outlook to approximately $2.74 billion, 31% annual growth, up from $2.65

Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences: https://mma.prnewswire.com/media/1063194/inhibrx_Logo.jpg 21st Annual Industry/Academia Precision Oncology & Radmed SymposiumNovember 5th, 2025 – La Jolla, California Title:DR5 Agonist Clinical Data in Chondrosarcoma, Colorectal